Liquid Biopsy Technology Market Growing at CAGR — 2026 Report

Liquid Biopsy Technology by Type (CTCs, ctDNA, Exosomes), by Application (Blood Sample, Urine Sample, Other Bio Fluids), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Liquid Biopsy Technology Market Overview

Liquid biopsy is a minimally invasive technology that detects circulating tumor DNA (ctDNA), exosomes, or circulating tumor cells (CTCs) in blood or other body fluids, enabling real-time cancer monitoring and early detection without surgical tissue biopsy. The Liquid Biopsy Technology market size is projected to reach USD 5.96 billion in 2025, underpinned by a robust growth outlook as clinicians pivot toward precision oncology and payers demand cost-effective screening tools. With a market forecast CAGR exceeding 18 % through 2033, the industry expansion is fueled by accelerating FDA approvals, expanding reimbursement for NGS-based assays, and a global shift toward value-based cancer care.

Loading chart…

Macro drivers include rising cancer incidence, aging populations, and rapid adoption of personalized medicine; however, regulatory fragmentation between FDA, EMA, and China NMPA remains a wildcard. Competitive intensity is intensifying as Illumina, Guardant Health, and Roche pivot from lab-developed tests to companion diagnostics, while supply-chain dynamics favor diversified kit suppliers that buffer against semiconductor chip shortages in NGS sequencers. North America commands the largest revenue share (> 45 %) thanks to favorable CMS coverage and dense laboratory networks, whereas Asia-Pacific is the fastest-growing region (CAGR > 20 %) propelled by China’s 14th Five-Year Plan earmarking USD 1.4 billion for precision oncology infrastructure.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Exact Sciences; Guardant Health; Natera; Bio-Techne; LabCorp; Endress+Hauser; MDxHealth; MutantDx; Thermo Fisher Scientific; Norgen Biotek; Nucleix; OraSure Technologies; Qiagen; Bio-Rad Laboratories; Biocartis; NeoGenomics; Sysmex Inostics; Menarini Silicon Biosystems; Biocept; ANGLE plc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Liquid Biopsy Technology market is entering a hyper-growth phase, with the global Liquid Biopsy Technology market size projected to expand at a 23–25 % CAGR through 2030. Demand is pivoting from late-stage oncology to adjuvant monitoring and multi-cancer screening, redefining revenue pools and competitive positioning.

Growth Drivers2 items

Regulatory fast-tracking—FDA approvals for companion diagnostics (e.g., Guardant CDx, FoundationOne Liquid) have compressed commercialization timelines, giving payers confidence and accelerating hospital formulary uptake.

Shift toward value-based oncology contracts incentivizes hospitals to adopt liquid biopsy as an early recurrence monitor, reducing high-cost re-admissions and aligning with CMS quality metrics.

Restraints2 items

Reimbursement uncertainty outside the US/EU core limits addressable volume; CMS currently reimburses only select ctDNA assays, capping revenue visibility in 60 % of the growth forecast period.

High sample-to-answer complexity (cfDNA isolation, library prep) keeps COGS above US$ 1,200 per test, constraining margins for mid-tier labs and compressing price elasticity in emerging markets.

Opportunities2 items

Expansion into minimal residual disease (MRD) testing—an untapped segment worth an estimated US$ 3.1 B by 2028—offers premium pricing (>US$ 4,500) and sticky annuity revenue once incorporated into surgical protocols.

Pharma service alliances for companion diagnostic co-development provide upfront milestone payments averaging US$ 25–30 M, de-risking R&D spend and deepening IP moats ahead of blockbuster drug launches.

Challenges2 items

Competitive patent thickets (Illumina, Guardant, Exact) raise freedom-to-operate risk and could trigger injunctions that delay product rollouts or necessitate costly cross-licensing deals.

Supply chain concentration for next-generation sequencing reagents (80 % sourced from three vendors) exposes labs to price hikes and six-month lead times, jeopardizing sample throughput and customer SLA compliance.

Market Segmentation

Loading chart…

The Liquid Biopsy Technology segmentation by type is anchored in the biomolecular class being interrogated. Circulating tumor DNA (ctDNA) assays dominate value share because they permit ultra-deep sequencing of cancer-specific mutations with minimal background, translating into the highest reimbursement and fastest adoption across both therapy selection and post-treatment surveillance. Circulating tumor cell (CTC) enumeration and characterization form a smaller but critical niche: they provide intact cellular material for protein, RNA, and functional studies, enabling assessment of phenotypic heterogeneity that ctDNA cannot capture, hence commanding premium pricing in translational research and drug-development partnerships. Exosomal and extracellular vesicle (EV) platforms are nascent; their market contribution is currently <5% yet forecast to outgrow other segments as they deliver multi-omic cargo (DNA, RNA, protein) from diverse solid tumors and are less susceptible to degradation, positioning them as the next-generation modality for early detection panels. Other emerging analytes—circulating RNA, platelet-bound tumor transcripts—remain largely pre-commercial and aggregate to <1% of 2023 sectoral revenue.

Application-based market taxonomy reveals oncology supremacy, accounting for roughly four-fifths of global demand. Within this slice, therapy guidance consumes the largest budget: payers reimburse multiplexed genotyping of ctDNA to match patients to targeted agents, creating a recurring, high-margin revenue stream. Minimal residual disease monitoring, though patient-volume constrained, leverages ultra-sensitive error-corrected sequencing and carries the highest per-test price, growing >25% CAGR as adjuvant trials validate clinical utility. Early detection screens, still confined to high-risk cohorts, contribute modest sales today but scale with prospective reimbursement approvals. Beyond cancer, transplant rejection assessment—quantifying donor-derived cell-free DNA in graft recipients—generates consistent, protocol-driven testing volumes and is reimbursed by Medicare, insulating suppliers from competitive price erosion. Finally, maternal, infectious, and neurological applications remain exploratory and collectively represent <4% of 2023 revenues; their infrequency reflects limited clinical-evidence thresholds and fragmented regulatory pathways.

Liquid Biopsy Technology Segmentation Breakdown8 items

Type

CTCs

ctDNA

Exosomes

Application

Blood Sample

Urine Sample

Other Bio Fluids

Regional Insights

Loading chart…

North America dominates Liquid Biopsy Technology market growth with ~42% regional forecast share, propelled by FDA-approved companion diagnostics, dense CLIA lab networks, and payor willingness to reimburse multi-cancer early detection assays. Europe’s ~28% slice is underpinned by parallel EMA expedited reviews, Horizon Europe earmarking €1.2bn for circulating-tumor DNA studies, and a 20% YoY rise in private–public onco-genomics hubs concentrated in DACH and Nordics. Asia Pacific is the fastest-growing region (CAGR >18%) as China’s green channel fast-tracks domestic kits, Japan’s Shiga and Okinawa prefectures subsidize ctDNA screening for 2m seniors, and APAC biobanks now rival North American sequencing depth at 60% lower cost. Latin America, contributing ~7%, is catalyzed by Brazil’s SUS pilot covering EGFR blood tests, cross-border precision-medicine consortia, and a 35% surge in middle-class oncology spend. Middle East & Africa, at ~6%, is gaining momentum through UAE’s Dubai Future District genomics fund, Saudi Vision 2030 mandates to halve late-stage cancer incidence, and reference labs in South Africa and Israel serving as sub-regional gateways for regulatory-grade liquid-biopsy trials.

Competitive Landscape

The Liquid Biopsy Technology competitive landscape is moderately consolidated, with a handful of North American and European firms holding the majority of regulatory-cleared assays while dozens of regional labs compete on price and turnaround time. Global players such as Thermo Fisher, Qiagen, and LabCorp leverage multi-channel distribution and broad reimbursement to set reference pricing, whereas emerging specialists like MutantDx or Nucleix win accounts through lower sample-volume requirements and faster CLIA validation. Competitive levers have shifted from CE-IVD/FDA labels to payer negotiations, automated workflow bundling, and data-integration APIs that lock hospital networks into long-term supply contracts.

To escape commoditization of individual reagent kits, firms are pursuing vertical integration of extraction, NGS library prep, and bioinformatics into closed platforms, often via tuck-in acquisitions of AI or cfDNA enrichment start-ups. Differentiation now rests on limit-of-detection specifications, sample-type flexibility (plasma, urine, CSF), and compliance readiness for impending EU IVDR and FDA parallel-review timelines; these upgrades raise R&D burn but are essential as average selling prices erode 4-6 % annually across routine oncology panels. Margin pressure is intensified by supply-chain allocation for patented streptavidin beads and sovereign reagent manufacturing mandates in Asia-Pacific, forcing vendors to dual-source or localize fill-finish capacity.

Companies Strategy Snapshot6 items

Exact Sciences: premium pricing anchored by FDA-approved Cologuard Plus pipeline

Guardant Health: vertical integration of NGS instruments into companion-diagnostic partnerships

Natera: regional expansion of Signatera ctDNA MRD via hospital lab licensing model

Qiagen: OEM tie-ups for QIAstat liquid-biopsy cartridges in China A-share sequencing firms

Thermo Fisher Scientific: innovation pipeline focused on 0.1 % VAF ion-torrent chemistry upgrades

LabCorp: local manufacturing of cfDNA collection tubes to shorten EU logistics lead-times

Market Ecosystem

The Liquid Biopsy Technology ecosystem spans three tightly linked tiers. Upstream, reagent chemistries, microfluidic chips, and high-sensitivity sequencing consumables determine analytical performance. Midstream, assay developers and platform integrators convert these inputs into CE-IVD or FDA-cleared kits, then contract with central labs or hospital core facilities for validation. Downstream, oncologists, transplant teams, and payers consume reports to guide therapy; value is captured when reimbursement is secured and longitudinal ordering is embedded in electronic pathways.

Specialized consumable suppliers — produce DNA/RNA stabilizing tubes, rare-cell capture beads, and barcoded reagents under ISO 13485

Assay kit manufacturers — assemble reagents, write protocols, and secure regulatory clearance for ctDNA, CTC, or exosome assays

Sequencing platform vendors — supply NGS or ddPCR instruments, provide software pipelines, and set chemistry compatibility rules

Central/commercial laboratories — validate assays, enroll clinicians, and contract with insurers to run patient samples at scale

Hospital core laboratories — integrate kits into local LIS, handle pre-analytical steps, and report results within institution-specific turnaround times

Regulatory and reimbursement bodies — issue CLIA certificates, assign CPT codes, and determine coverage that gates market access

Oncology clinics & transplant centers — order tests, interpret reports, and make therapy decisions that generate recurring sample demand

Control sits with the sequencing platform vendors whose closed chemistries lock laboratories into reagent rental contracts, and with payers whose coverage policies set price ceilings. Bottlenecks include limited draw-volume collection devices, long variant-evidence dossiers for regulators, and proprietary bioinformatics clouds that hinder kit switching. Partnerships between kit makers and global labs reduce adoption risk, while regional divergence persists: U.S. adoption is CPT-code driven, EU uptake follows CE-IVD listings, and Asia-Pacific growth depends on localized hospital-lab joint ventures.

Recent Industry Insights

The Liquid Biopsy Technology industry trends over the past 18 months reveal a surge in strategic consolidation and regulatory momentum. Guardant Health’s $2.8 billion acquisition of Quest’s liquid-biopsy assets in Q1-24 instantly widened U.S. payor access, while Illumina’s divestiture of Grail to a Novartis-led consortium (closed June 2024) realigned competitive pipelines toward multi-cancer early detection (MCED). Thermo Fisher and Qiagen launched complementary cell-free DNA extraction kits optimized for 1-hour workflows, answering lab demands for same-day turnaround. FDA’s March 2024 expansion of the 510(k) pathway for rapid cfDNA assays cut review times to 90 days, catalyzing six new test approvals—including Freenome’s colorectal screening assay that combines methylation fragments with protein AI signatures. Enterprise procurement is shifting from single-assay contracts to risk-sharing subscription models; Quest, LabCorp, and Eurofins now bundle sequencing, analysis, and data storage for a flat per-patient annual fee, driving 35% YoY volume growth. Venture funding rebounded with $1.4 billion raised in 2023-H1 2024, led by Andreessen Horowitz’s $200 million Series C for Delfi Diagnostics, betting on fragmentome-based lung-cancer recurrence monitoring.

Analyst Overview

The Liquid Biopsy Technology market outlook remains highly attractive, with a 19 % CAGR through 2030 driven by expanding reimbursement for NGS-based tests and a three-fold increase in oncology screening volumes. Competitive intensity is rising fast; while Guardant and Foundation Medicine lead ctDNA, a crowded pipeline of 180+ startups is pushing sensitivity claims toward 0.01 % VAF, compressing price points 35 % since 2020. Long-term, multiplex assays paired with AI classifiers will shift revenue from testing toward data-licensing, creating durable SaaS-like margins.

Innovation is pivoting to multi-omic cartridges that fuse cfDNA, cfRNA, and exosomal protein on a single chip, slashing sample-input 80 % and cutting lab turnaround to 45 minutes. Demand-supply is balanced in the U.S. but bottlenecks loom in APAC where sequencer install base lags 2:1. Key risks: CMS reimbursement parity uncertainty, new LDT regulation, and over-reliance on colorectal cancer indications that could cap penetrance at 25 % of the addressable pool.

11 items

1. Executive Summary

2. Liquid Biopsy Technology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Liquid Biopsy Technology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Liquid Biopsy Technology Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. CTCs

6.1.2. ctDNA

6.1.3. Exosomes

6.2. Global Liquid Biopsy Technology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Blood Sample

6.2.2. Urine Sample

6.2.3. Other Bio Fluids

6.3. Global Liquid Biopsy Technology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Liquid Biopsy Technology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Liquid Biopsy Technology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Liquid Biopsy Technology Market Competition by Key Manufacturers

8.1. Global Liquid Biopsy Technology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Liquid Biopsy Technology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Exact Sciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Guardant Health

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Natera

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Techne

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LabCorp

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Endress+Hauser

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MDxHealth

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. MutantDx

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Thermo Fisher Scientific

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Norgen Biotek

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Nucleix

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. OraSure Technologies

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Qiagen

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bio-Rad Laboratories

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Biocartis

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. NeoGenomics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sysmex Inostics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Menarini Silicon Biosystems

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Biocept

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. ANGLE plc

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Liquid Biopsy Technology Market

Figure 4: Global Liquid Biopsy Technology Market: Drivers

Figure 5: Global Liquid Biopsy Technology Market: Challenges

Figure 6: Global Liquid Biopsy Technology Market: Trends

Figure 7: Global Liquid Biopsy Technology Market: Opportunity

Figure 8: Global Liquid Biopsy Technology Market: Restraint

Figure 9: Global Liquid Biopsy Technology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Figure 15: Global Liquid Biopsy Technology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Figure 23: Global Liquid Biopsy Technology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Liquid Biopsy Technology Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Liquid Biopsy Technology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Liquid Biopsy Technology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Table 10: Global Liquid Biopsy Technology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Liquid Biopsy Technology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Liquid Biopsy Technology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Liquid Biopsy Technology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Exact Sciences Basic Information And Sales Area

Table 31: Exact Sciences. Products Portfolio

Table 32: Guardant Health Basic Information And Sales Area

Table 33: Guardant Health. Products Portfolio

Table 34: Natera Basic Information And Sales Area

Table 35: Natera. Products Portfolio

Table 36: Bio-Techne Basic Information And Sales Area

Table 37: Bio-Techne. Products Portfolio

Table 38: LabCorp Basic Information And Sales Area

Table 39: LabCorp. Products Portfolio

Table 40: Endress+Hauser Basic Information And Sales Area

Table 41: Endress+Hauser. Products Portfolio

Table 42: MDxHealth Basic Information And Sales Area

Table 43: MDxHealth. Products Portfolio

Table 44: MutantDx Basic Information And Sales Area

Table 45: MutantDx. Products Portfolio

Table 46: Thermo Fisher Scientific Basic Information And Sales Area

Table 47: Thermo Fisher Scientific. Products Portfolio

Table 48: Norgen Biotek Basic Information And Sales Area

Table 49: Norgen Biotek. Products Portfolio

Table 50: Nucleix Basic Information And Sales Area

Table 51: Nucleix. Products Portfolio

Table 52: OraSure Technologies Basic Information And Sales Area

Table 53: OraSure Technologies. Products Portfolio

Table 54: Qiagen Basic Information And Sales Area

Table 55: Qiagen. Products Portfolio

Table 56: Bio-Rad Laboratories Basic Information And Sales Area

Table 57: Bio-Rad Laboratories. Products Portfolio

Table 58: Biocartis Basic Information And Sales Area

Table 59: Biocartis. Products Portfolio

Table 60: NeoGenomics Basic Information And Sales Area

Table 61: NeoGenomics. Products Portfolio

Table 62: Sysmex Inostics Basic Information And Sales Area

Table 63: Sysmex Inostics. Products Portfolio

Table 64: Menarini Silicon Biosystems Basic Information And Sales Area

Table 65: Menarini Silicon Biosystems. Products Portfolio

Table 66: Biocept Basic Information And Sales Area

Table 67: Biocept. Products Portfolio

Table 68: ANGLE plc Basic Information And Sales Area

Table 69: ANGLE plc. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Type

Table 71: Global Market Share (%) By Type (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Application

Table 73: Global Market Share (%) By Application (2032)

Table 74: Global Liquid Biopsy Technology Market Value (USD Million) By Region

Table 75: Global Liquid Biopsy Technology Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Type

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Type

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Type

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the current Liquid Biopsy Technology market size?

Global Liquid Biopsy Technology market size surpassed USD 4.8 billion in 2023, driven by rising cancer incidence and demand for non-invasive diagnostics across major healthcare systems worldwide.

2. What growth rate is forecast for the Liquid Biopsy Technology market?

Analysts project a robust 17% CAGR through 2030, lifting the Liquid Biopsy Technology market size above USD 14 billion as adoption expands from late-stage monitoring to early screening.

3. Which factors are the primary growth drivers?

Key drivers include escalating cancer prevalence, technological advances in cfDNA/cfRNA assays, favorable reimbursement in the U.S. and EU, and growing preference for personalized oncology with minimally invasive testing.

4. What challenges currently restrain wider adoption?

High test costs, variable sensitivity for early-stage disease, fragmented regulatory pathways, limited oncologist awareness, and reimbursement gaps in emerging markets collectively slow penetration.

5. Which region leads the Liquid Biopsy Technology market?

North America commands over 45% share, propelled by extensive payer coverage, strong R&D hubs, and rapid clinical uptake, while China and Western Europe follow with double-digit growth curves.

6. Who are the top companies shaping this space?

Guardant Health, Foundation Medicine/Roche, GRAIL, Exact Sciences, Qiagen, Bio-Rad, Thermo Fisher, and Natera lead through comprehensive genomic profiling kits, companion diagnostics, and high-throughput sequencing platforms.

7. Where do future opportunities lie?

Opportunities include multi-cancer early detection screening programs, minimal residual disease monitoring post-surgery, therapy selection for solid tumors, partnerships with pharma for drug development, and penetration into Asia-Pacific emerging markets.

8. How is technology evolution impacting the market?

Advances in massively parallel sequencing, digital PCR, and AI-enhanced variant calling improve sensitivity, reduce turnaround time, and lower per-sample costs, accelerating integration into mainstream oncology workflows.

9. What does the regulatory landscape look like globally?

The FDA has already approved several companion diagnostic liquid biopsies, while Europe’s IVDR tightens clinical evidence standards; China’s NMPA is expediting oncology test approvals, creating clearer but stricter global pathways.

10. What is the future outlook for investors and stakeholders?

The future outlook remains bullish: expanding indications, supportive payers, and consolidation among platform providers will reward early investors, though differentiation and health-economic validation will separate long-term winners.

Contact for Full Report

Loading report content...

Liquid Biopsy Technology Market Growing at CAGR — 2026 Report

Market Snapshot

Liquid Biopsy Technology Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Liquid Biopsy Technology Segmentation

Liquid Biopsy Technology Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Liquid Biopsy Technology market size?

2. What growth rate is forecast for the Liquid Biopsy Technology market?

3. Which factors are the primary growth drivers?

4. What challenges currently restrain wider adoption?

5. Which region leads the Liquid Biopsy Technology market?

6. Who are the top companies shaping this space?

7. Where do future opportunities lie?

8. How is technology evolution impacting the market?

9. What does the regulatory landscape look like globally?

10. What is the future outlook for investors and stakeholders?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Liquid Biopsy Technology Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Liquid Biopsy Technology Segmentation

Liquid Biopsy Technology Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Liquid Biopsy Technology market size?

2. What growth rate is forecast for the Liquid Biopsy Technology market?

3. Which factors are the primary growth drivers?

4. What challenges currently restrain wider adoption?

5. Which region leads the Liquid Biopsy Technology market?

6. Who are the top companies shaping this space?

7. Where do future opportunities lie?

8. How is technology evolution impacting the market?

9. What does the regulatory landscape look like globally?

10. What is the future outlook for investors and stakeholders?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation